← The SEC Ephemeris: the whole map
NeuroDerm, Ltd. carbidopa levodopa
In the graph: all 2 documents (5 pages).
- Application
- NDA 218317
- Ticker
- NeuroDerm, Ltd.
- Product
- carbidopa levodopa
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- October 21, 2025 · May 24, 2024
From FDA letters and SEC filings. Not investment or medical advice.